Table 2.
Acute and late adverse events (grade ≥ 2) for all patients (n = 21)
| Grade 2 (%) | Grade 3 (%) | Grade 4 (%) | |
|---|---|---|---|
| Acute adverse event | |||
| Mucositis | 9 (43) | 2 (10) | 0 (0) |
| Dermatitis | 8 (38) | 0 (0) | 0 (0) |
| Conjunctivitis | 4 (19) | 0 (0) | 0 (0) |
| Thrombocytopenia | 5 (24) | 1 (5) | 0 (0) |
| Leukopenia | 4 (19) | 5 (24) | 0 (0) |
| Anemia | 3 (14) | 0 (0) | 0 (0) |
| Dysgeusia | 1 (5) | 0 (0) | 0 (0) |
| Late adverse event | |||
| Mucositis | 4 (19) | 0 (0) | 0 (0) |
| Dermatitis | 0 (0) | 0 (0) | 0 (0) |
| Nasal congestion | 3 (14) | 0 (0) | 0 (0) |
| Nasolacrimal duct obstruction | 0 (0) | 0 (0) | 0 (0) |
| Sinusitis | 3 (14) | 0 (0) | 0 (0) |
| Otitis media | 3 (14) | 0 (0) | 0 (0) |
| Maxilla osteonecrosis | 3 (14) | 0 (0) | 0 (0) |
| Oronasal/Oroantral fistula | 1 (5) | 0 (0) | 0 (0) |